Enacts new subsection (b2) to GS 90-85.28 to prohibit a pharmacist from substituting any drug product that is not an equivalent drug product identified on the prescription unless, before substituting, the pharmacist: (1) obtains and documents the prescriber’s written or verbal consent, (2) obtains and documents the patient’s written or verbal consent, and (3) maintains consent documentation on file. Amends GS 90-85.27, clarifying the definition for equivalent drug product to mean a drug product with the same established name, active ingredient, strength, quantity, and dosage form, which is listed as therapeutically equivalent to the drug product on the prescription under the most recent version of the Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations.